The R&D organisation drives therapeutic innovation from the lab bench to the patient bedside. It develops DNDi’s portfolio of drug candidates from the onset (with the design of target product profiles) to the end point (enabling patients’ access to the new treatments). With members located in various DNDi offices worldwide, R&D teams are key enablers of DNDi’s virtual research model which relies on collaborative partnerships with industry and science partners worldwide, fully inclusive of LMICs clinicians and researchers. Projects are run by project leaders and team members regrouping needed expertise from all DNDi functions, beyond R&D.
As a strategic transversal R&D function, the Pharmaceutical Development department advances the design, development, and industrialisation of new treatments by leveraging an external network of partners with diverse product development, drug delivery and manufacturing capabilities. Its team members lead pharmaceutical development, regulatory CMC, manufacturing, and supply activities across our portfolio, as well as building external partner capabilities, and introducing new projects and technologies.
The Pharmaceutical Development Team also supports projects for the Global Antibiotic Research and Development Partnership (GARDP).
The Drugs for Neglected Diseases initiative (DNDi) is an international, not-for-profit research and development (R&D) organization that develops and delivers new treatments for neglected diseases affecting millions of the world’s poorest people.
Together with more than 200 public research and industry allies worldwide, we use the power of partnership, innovation, open science, and advocacy to find solutions to a great injustice: the lack of medicines for life-threatening diseases that disproportionately impact poor and marginalized people. Driven by collaboration, not competition, and by patients’ needs, not profits, we promote equitable access, foster inclusive and sustainable solutions, and advocate for a more effective global biomedical R&D system that meets the needs of neglected patients.
Since our inception, DNDi has delivered 13 new treatments for people with sleeping sickness, visceral leishmaniasis, Chagas disease, HIV, hepatitis C, and malaria that have saved millions of lives. We aim to deliver a total of 25 new treatments by 2028– addressing R&D gaps for neglected tropical diseases and viral infections, including new pandemic-prone diseases (such as COVID-19) and climate-sensitive diseases (such as Dengue) with a focus on the needs of patients in low- and middle-income countries.
With more than 200 employees of 30+ nationalities located in eight offices on four continents, DNDi is committed to diversity, equity, and inclusion as essential parts of our culture and key drivers of our success. We encourage candidates of diverse profiles and backgrounds to apply.
Overall Purpose:
The Pharmaceutical Development Officer coordinates Chemistry, Manufacturing and Control (CMC) activities. This role also provides support to the whole Pharmaceutical Development team. This role will contribute to the development and management of pharmaceutical quality systems to assure compliance with GMP and GDP requirements.
Contribution
This role provides specialist services to operational line or project team, working within tried and tested policy, process or practice. This role solves non-routine problems on a case by case/project basis, in consultation with other colleagues or supervisors.
Tasks and Responsibilities
DNDi is committed to building a diverse, equitable and truly inclusive organisation. Our success and global reach are dependent upon our ability to encourage diversity and draw on the skills, understanding and experience of all our people. We particularly welcome applications from those who are underrepresented in at DNDi and across the sector, especially women, and including, but not limited to, black and minority ethnic candidates, and those with other protected characteristic.